{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T21:08:05Z","timestamp":1789679285231,"version":"4.0.1"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jdsjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dermatological Science"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jdermsci.2026.08.009","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:15:26Z","timestamp":1788448526000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Enfortumab vedotin-related cutaneous toxicity: Clinical features, pathogenesis and management"],"prefix":"10.1016","author":[{"given":"Kazumasa","family":"Oya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdermsci.2026.08.009_bib1","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/s41568-025-00869-w","article-title":"Unveiling the molecular and immunological drivers of antibody-drug conjugates in cancer treatment","volume":"25","author":"Zippelius","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jdermsci.2026.08.009_bib2","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217681","article-title":"Nectin-4 expression patterns and therapeutics in oncology","volume":"622","author":"Nikanjam","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1397692","article-title":"Post-marketing drug safety surveillance of enfortumab vedotin: an observational pharmacovigilance study based on a real-world database","volume":"15","author":"Yu","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.euros.2025.08.001","article-title":"One man's meat is another man's poison: high incidence of severe cutaneous drug reactions induced by Enfortumab vedotin","volume":"80","author":"Pan","year":"2025","journal-title":"Eur. Urol. Open. Sci."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.71284","article-title":"Treatment-related adverse events and associated outcomes in patients with advanced urothelial carcinoma treated with enfortumab vedotin: analysis of the UNITE study","volume":"14","author":"Nizam","year":"2025","journal-title":"Cancer Med."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib7","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1111\/1346-8138.15577","article-title":"Severe eczematoid and lichenoid eruption with full-thickness epidermal necrosis developing from metastatic urothelial cancer treated with enfortumab vedotin","volume":"47","author":"Sasaki","year":"2020","journal-title":"J. Dermatol."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jdcr.2021.05.020","article-title":"Cutaneous reactions with enfortumab vedotin: a case series and review of the literature","volume":"14","author":"Dobry","year":"2021","journal-title":"JAAD Case Rep."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib9","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/ddg.15453","article-title":"SDRIFE and bullous reaction after treatment with enfortumab vedotin plus pembrolizumab: case series","volume":"22","author":"Lluch-Galcer\u00e1","year":"2024","journal-title":"J. Dtsch Dermatol. Ges."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib10","doi-asserted-by":"crossref","first-page":"e1009","DOI":"10.1111\/jdv.18406","article-title":"Enfortumab vedotin-induced cutaneous adverse events manifesting as miliaria-like eruptions with the presence of keratinocyte apoptosis in clinically intact skin","volume":"36","author":"Oya","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib11","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejca.2022.02.020","article-title":"Keratinocyte apoptosis was present in clinically intact skin in a patient treated with enfortumab vedotin","volume":"167","author":"Oya","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jdermsci.2026.08.009_bib12","first-page":"1781","article-title":"A distinctive bullous skin reaction associated with enfortumab vedotin-ejfv treatment for metastatic urothelial cancer: a case report","volume":"19","author":"Krause","year":"2021","journal-title":"J. Dtsch Dermatol. Ges."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib13","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejca.2022.02.019","article-title":"Life-threatening skin reaction with Enfortumab Vedotin: Six cases","volume":"167","author":"Guerrois","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jdermsci.2026.08.009_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.621591","volume":"11","author":"Viscuse","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib15","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1684\/ejd.2025.4864","article-title":"Erythema multiforme-like eruption with severe epidermal necrosis after administration of enfortumab vedotin","volume":"35","author":"Imura","year":"2025","journal-title":"Eur. J. Dermatol."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib16","doi-asserted-by":"crossref","first-page":"e486","DOI":"10.1111\/jdv.70238","article-title":"Clinical and histopathological features of alopecia associated with enfortumab vedotin treatment","volume":"40","author":"Oya","year":"2026","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib17","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jdcr.2024.12.037","article-title":"Recognition and management of adverse cutaneous reactions in patients on enfortumab vedotin and pembrolizumab in the inpatient setting","volume":"58","author":"Myers","year":"2025","journal-title":"JAAD Case Rep."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib18","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ajhg.2010.07.003","article-title":"Mutations in PVRL4, encoding cell adhesion molecule nectin-4, cause ectodermal dysplasia-syndactyly syndrome","volume":"87","author":"Brancati","year":"2010","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib19","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1146\/annurev.cellbio.24.110707.175339","article-title":"The immunoglobulin-like cell adhesion molecule nectin and its associated protein afadin","volume":"24","author":"Takai","year":"2008","journal-title":"Annu. Rev. Cell. Dev. Biol."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib20","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00018-014-1763-4","article-title":"Nectin family of cell-adhesion molecules: structural and molecular aspects of function and specificity","volume":"72","author":"Samanta","year":"2015","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib21","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.194290","article-title":"Nectin-4 reduces T cell effector function and is a therapeutic target in pancreatic cancer","volume":"11","author":"Heiduk","year":"2026","journal-title":"JCI Insight"},{"key":"10.1016\/j.jdermsci.2026.08.009_bib22","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2025.05.016","article-title":"Enfortumab vedotin-related skin toxicities in patients with urothelial carcinoma: A systematic review and meta-analysis","volume":"43","author":"Gazzoni","year":"2025","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib24","article-title":"Incidence, risk factors, and clinical implications of enfortumab vedotin-related cutaneous toxicity in urothelial carcinoma: a large-scale, real-world study in Japan","volume":"7","author":"Kita","year":"2025","journal-title":"ESMO Real. World Data Digit. Oncol."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115427","article-title":"Association between drug-related cutaneous adverse events and survival outcomes in patients treated with enfortumab vedotin","volume":"222","author":"Belka\u00efd","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jdermsci.2026.08.009_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2025.102301","article-title":"Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Comprehensive Treatment Outcomes and Prognostic Insights From a Multicenter Real-World Study (YUSHIMA Study)","volume":"23","author":"Nakamura","year":"2025","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.jdermsci.2026.08.009_bib27","doi-asserted-by":"crossref","first-page":"e303","DOI":"10.1111\/1346-8138.16809","article-title":"Skin fragility: Caution is required with the use of pain relief patches during enfortumab vedotin treatment","volume":"50","author":"Matsuyoshi","year":"2023","journal-title":"J. Dermatol."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib28","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1093\/oncolo\/oyac001","article-title":"Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin","volume":"27","author":"Lacouture","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.jdermsci.2026.08.009_bib29","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1111\/1346-8138.17901","article-title":"Enfortumab Vedotin-Related Skin Toxicities: Insights From Clinical and Histopathological Analysis","volume":"52","author":"Kuma","year":"2025","journal-title":"J. Dermatol."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib30","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/cup.14689","article-title":"Enfortumab vedotin-induced cutaneous eruption: Ring mitotic figures as a distinctive histopathologic feature","volume":"51","author":"Sport","year":"2024","journal-title":"J. Cutan. Pathol."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib31","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.jaad.2020.11.067","article-title":"Clinicopathologic characterization of enfortumab vedotin-associated cutaneous toxicity in patients with urothelial carcinoma","volume":"85","author":"Hirotsu","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib32","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/jdv.13475","article-title":"Taxanes-induced cutaneous eruption: another histopathologic mimicker of malignancy","volume":"30","author":"Prieto-Torres","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib33","doi-asserted-by":"crossref","first-page":"e817","DOI":"10.1111\/1346-8138.17816","article-title":"Two Cases of Enfortumab Vedotin-Induced Drug Eruption Diagnosed Based on the Distinctive Epidermal Mitotic Figures in Patients Receiving Combination Therapy With Pembrolizumab","volume":"52","author":"Ito","year":"2025","journal-title":"J. Dermatol."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib34","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jdcr.2024.10.019","article-title":"Use of dupilumab to manage a grade 3 cutaneous adverse effect from enfortumab vedotin\/pembrolizumab treatment in a patient with metastatic urothelial carcinoma","volume":"56","author":"Gillis","year":"2025","journal-title":"JAAD Case Rep."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib35","doi-asserted-by":"crossref","DOI":"10.5070\/D3252042890","article-title":"Cutaneous toxicity associated with enfortumab vedotin treatment of metastatic urothelial carcinoma","volume":"25","author":"Wu","year":"2019","journal-title":"Dermatol. Online J."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib36","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.euros.2024.09.011","article-title":"Safety and Efficacy of Prophylactic Topical Steroid Administration for Enfortumab Vedotin-related Cutaneous Toxicity","volume":"70","author":"Kita","year":"2024","journal-title":"Eur. Urol. Open. Sci."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib37","article-title":"Severe Cutaneous Toxicity in A 67-Year-Old Patient with Metastatic Urothelial Carcinoma Undergoing Therapy with Enfortumab Vedotin and Pembrolizumab","volume":"11","author":"M\u00fcller","year":"2024","journal-title":"Eur. J. Case Rep. Intern. Med."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib38","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/iju5.12562","article-title":"Toxic epidermal necrolysis after the administration of enfortumab vedotin for urinary bladder urothelial carcinoma","volume":"6","author":"Mimura","year":"2023","journal-title":"IJU Case Rep."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib39","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jdcr.2023.10.025","article-title":"Enfortumab vedotin toxic epidermal necrolysis-like blistering dermatosis: A case series and review of the literature","volume":"43","author":"Khanjar","year":"2024","journal-title":"JAAD Case Rep."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib40","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1111\/1346-8138.16646","article-title":"Cutaneous toxicity with suprabasal blisters and dyskeratosis following administration of enfortumab vedotin","volume":"50","author":"Hasui","year":"2023","journal-title":"J. Dermatol."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib41","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jaad.2008.05.018","article-title":"Toxic erythema of chemotherapy: A useful clinical term","volume":"59","author":"Bolognia","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib42","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jdcr.2022.01.005","article-title":"Severe cutaneous drug toxicity following enfortumab vedotin treatment for metastatic urothelial carcinoma","volume":"21","author":"Enescu","year":"2022","journal-title":"JAAD Case Rep."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2021.115534","article-title":"Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): Mechanistic insights into MMAE ADC peripheral neuropathy","volume":"421","author":"Best","year":"2021","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib44","doi-asserted-by":"crossref","first-page":"e453","DOI":"10.1111\/1346-8138.16567","article-title":"Intertriginous erythema associated with enfortumab vedotin, a nectin-4-targeting antibody-drug conjugate, in a case with metastatic urothelial cancer: Immunohistochemical evidence for molecular-targeted eruption","volume":"49","author":"Hasegawa","year":"2022","journal-title":"J. Dermatol."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib45","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.18572","article-title":"Exploring membranous NECTIN-4 expression patterns and enfortumab vedotin response in prostate cancer","volume":"28","author":"Weiten","year":"2024","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib46","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/annonc\/mdw678","article-title":"Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer","volume":"28","author":"M-Rabet","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib47","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00358","article-title":"A role for PVRL4-driven cell\u2013cell interactions in tumorigenesis","volume":"2","author":"Pavlova","year":"2013","journal-title":"eLife"},{"key":"10.1016\/j.jdermsci.2026.08.009_bib48","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1016\/j.celrep.2019.08.057","article-title":"GEF-H1 signaling upon microtubule destabilization is required for dendritic cell activation and specific anti-tumor responses","volume":"28","author":"Kashyap","year":"2019","journal-title":"Cell. Rep."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib49","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1158\/0008-5472.CAN-25-0024","article-title":"Targeting sialylation enhances the therapeutic efficacy of the nectin-4-targeted antibody-drug conjugate enfortumab vedotin in bladder cancer","volume":"86","author":"Wu","year":"2026","journal-title":"Cancer Res."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib50","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1111\/ijd.70258","article-title":"Clinicopathologic and immunohistochemical features of enfortumab vedotin-induced cutaneous toxicity","volume":"65","author":"Repetto","year":"2026","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib51","doi-asserted-by":"crossref","DOI":"10.1111\/iju.70425","article-title":"Association of prophylactic intravenous corticosteroid premedication with toxicity and survival in patients receiving enfortumab vedotin for locally advanced or metastatic urothelial carcinoma","volume":"33","author":"Shinohara","year":"2026","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib52","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1111\/1346-8138.70136","article-title":"Guidelines for the management of Stevens-Johnson syndrome and toxic epidermal necrolysis 2025 supplement","volume":"53","author":"Watanabe","year":"2026","journal-title":"J. Dermatol."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib53","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1111\/jdv.19454","article-title":"Skin toxicity of enfortumab vedotin: Proposal of a specific management algorithm","volume":"38","author":"Ingen-Housz-Oro","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib54","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/iju5.70036","article-title":"Enfortumab vedotin-induced toxic epidermal necrolysis in metastatic urothelial carcinoma complicated by severe gastrointestinal bleeding","volume":"8","author":"Matsuyama","year":"2025","journal-title":"IJU Case Rep."},{"key":"10.1016\/j.jdermsci.2026.08.009_bib55","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.22.02887","article-title":"Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer","volume":"41","author":"O'Donnell","year":"2023","journal-title":"J. Clin. Oncol."}],"container-title":["Journal of Dermatological Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181126001507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181126001507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:57:05Z","timestamp":1789678625000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923181126001507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":55,"alternative-id":["S0923181126001507"],"URL":"https:\/\/doi.org\/10.1016\/j.jdermsci.2026.08.009","relation":{},"ISSN":["0923-1811"],"issn-type":[{"value":"0923-1811","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enfortumab vedotin-related cutaneous toxicity: Clinical features, pathogenesis and management","name":"articletitle","label":"Article Title"},{"value":"Journal of Dermatological Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdermsci.2026.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Japanese Society for Investigative Dermatology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}